Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7287242 | 0.94 | NQO1 (0.54) | NQO1SIGMAR1MAPTRAB9AL3MBTL1 | |
| SCHEMBL1610396 | 0.88 | NQO1 (0.61) | NQO1SIGMAR1MAPTRAB9AL3MBTL1 | |
| SCHEMBL4248652 | 0.87 | NQO1 (0.67) | NQO1SIGMAR1MAPTRAB9AL3MBTL1 | |
| SCHEMBL7295478 | 0.86 | LMNA (0.55) | L3MBTL1TSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10575040 | 0.85 | NQO1 (0.64) | NQO1SIGMAR1MAPTRAB9AL3MBTL1 | |
| SCHEMBL8733183 | 0.85 | LMNA (0.56) | L3MBTL1ALDH1A1SMN1; SMN2LTA4HTHRB | |
| SCHEMBL8986268 | 0.83 | NQO1 (0.61) | NQO1SIGMAR1MAPTRAB9AL3MBTL1 | |
| SCHEMBL57081 | 0.83 | LMNA (0.56) | MAPTRAB9AALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL11042252 | 0.82 | LMNA (0.59) | MAPTRAB9ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL12251519 | 0.82 | MAPT (0.66) | NQO1SIGMAR1MAPTRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101522657-B | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO.,LTD. (JP) | 2014-10-15 | — | — | CN | disclosed |
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| CN-103224488-A | Heterocyclic compound or salt thereof | OTSUKA PHARMA CO LTD | 2013-07-31 | — | — | CN | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| CN-1993339-B | Aromatic compound | OTSUKA PHARMA CO LTD | 2013-05-22 | — | — | CN | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-5464833-A | Anticarcinogenic agents, antiretrovirus agents or autoimmune diseases | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-07 | — | — | US | disclosed |
| EP-0623598-A1 | APOPTOSIS REGULATOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-09 | — | — | EP | disclosed |
| CN-1024797-C | Indole derivatives | OTSUKA CHEMICAL CO LTD (JP) | 1994-06-01 | — | — | CN | disclosed |
| EP-0569592-A1 | CARBOSTYRIL DERIVATIVE AND PLATELET AGGLUTINATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-18 | — | — | EP | disclosed |
| US-5238938-A | Nephrosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-24 | — | — | US | disclosed |
| CN-1049155-A | INDOLE DERIVATIVES | OTSUKA CHEMICAL CO LTD (JP) | 1991-02-13 | — | — | CN | disclosed |
| EP-0411150-A1 | INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-06 | — | — | EP | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
| US-4379788-A | HYPOTENSIVES, ANTIARRHYTHMIA, B-BLOCKERS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-04-12 | — | — | US | disclosed |
| EP-0002604-A1 | Quaternary ammonium salts, and their formulations and preparation | ELI LILLY AND COMPANY (US) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | NQO1 255/4885SIGMAR1 52/4885MAPT 4315/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | NQO1 1307/4885SIGMAR1 549/4885MAPT 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.